Massachusetts Institute of Technology

Leland Stanford Junior University

Adimab, LLC

Ohio State Innovation Foundation

Memorial Sloan Kettering Cancer Center

Nodus Therapeutics, Inc.

The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Fred Hutchinson Cancer Center

Karl Dane Wittrup

Darrell J Irvine

Jennifer R Cochran

Eric Krauland

Byron Hua Kwan

Laura M Walker

Alice Tzeng

Noor Momin

Nai-Kong V Cheung

Ron Weiss

Yizhou Dong

Steven M Larson

Hong Xu

Sarah M Cheal

Tyson Moyer

Yingzhong Li

Yash Agarwal

Chensu Wang

Sangeeta N Bhatia

Angela M Belcher

Kai W Wucherpfennig

Douglas A Lauffenburger

Beau R Peelle

Andrew David Luster

Andrew Warren

Oliver Press

Jaideep S Dudani

Damian J Green

Kelly Dare Moynihan

Balaji M Rao

Benjamin Ezra Epstein

Nathan D Mathewson

Cary Francis Opel

Yukang Lin

Magnolia Chinn

Joseph Palmeri

Shuning Gai

Benjamin Cossette

Leyuan Ma

Jamie B Spangler

Naveen Mehta

Brian L Ross

Kelly Davis Orcutt

Naveen K Mehta

Byong Ha Kang

Alessandro Angelini

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof

The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.

Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs

The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy

The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.

Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancers

A method of broadening epitopic coverage of an antigen of interest, wherein a first sample of the antigen of interest is contacted with a first plurality of host cells collectively expressing a first library of antibodies. Host cells expressing antibodies that bind to the antigen are then collected from among the first plurality of host cells, and a composition is prepared comprising a polyclonal mixture of antibodies expressed by these host cells. A second sample of the antigen of interest is then contacted with an aliquot of the prepared composition and a second plurality of host cells collectively expressing a second library of antibodies. Host cells expressing antibodies that bind to the second sample of the antigen are then collected from among the second plurality of host cells.

Polyclonal mixtures of antibodies, and methods of making and using them

The present disclosure provides immunomodulatory fusion proteins comprising a collagen-binding domain operably linked to an immunomodulatory domain. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

Collagen-localized immunomodulatory molecules and methods thereof

The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.

Bispecific antibodies specific for treating hematological malignancies

Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof

The present disclosure provides for fusion proteins comprising multipsecific variable regions that bind more than one ELR+ CXC chemokine.

Multiple specificity binders of CXC chemokines

The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Monoclonal antibodies that bind human CD161

In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of pro teases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

Methods to specifically profile protease activity at lymph nodes

Combination immunotherapy dosing regimen for immune checkpoint blockade

Growing community of inventors

Chestnut Hill, MA, United States of America

Karl Dane Wittrup